<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Current guidelines for the management of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> advocate the attainment of sustained near <z:mpath ids='MPATH_458'>normal</z:mpath> glycaemia levels </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> is widely accepted as the treatment of choice for the initiation of pharmacotherapy; however, secondary failure of oral monotherapy occurs in 60% of patients resulting in the need for multiple pharmacotherapies </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy-related consequences of treatment, such as <z:mp ids='MP_0005456'>weight gain</z:mp> and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> impact on the cost-effectiveness profile of various agents </plain></SENT>
<SENT sid="3" pm="."><plain>We therefore sought to ascertain the respective contribution of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, weight change and improved blood <z:chebi fb="105" ids="17234">glucose</z:chebi> control on second-line therapy options added to <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: This study uses a simulation model designed to evaluate the cost utility of new therapies in a population of patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Standard model outputs include incidence of micro- and macrovascular complications and <z:mp ids='MP_0002055'>diabetes</z:mp>-specific and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The mean discounted quality-adjusted life year (QALY) predicted by the model was 12.31 years </plain></SENT>
<SENT sid="7" pm="."><plain>Reducing Glycosylated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA1c) by 1% gave a predicted gain of 0.413 QALYs per patient </plain></SENT>
<SENT sid="8" pm="."><plain>A 3-kg <z:hpo ids='HP_0001824'>weight loss</z:hpo> and 30% reduction in <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> frequency produced a combined QALY gain of 0.355, whereas the reverse gave a QALY decrement of 0.356 </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The results of this analysis quantify the QALY decrement that may result from adverse therapy effects </plain></SENT>
<SENT sid="10" pm="."><plain>The beneficial effects of improved glycaemic control on QALYs may be offset by characteristic treatment-specific adverse effects, such as <z:mp ids='MP_0005456'>weight gain</z:mp> and <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> frequency </plain></SENT>
</text></document>